Discovery and development of safe-in-man broad-spectrum antiviral agents

Show full item record



Permalink

http://hdl.handle.net/10138/316038

Citation

Andersen , P I , Ianevski , A , Lysvand , H , Oksenych , V , Bjørås , M , Telling , K , Lutsar , I , Dampis , U , Irie , Y , Tenson , T , Kantele , A & Kainov , D 2020 , ' Discovery and development of safe-in-man broad-spectrum antiviral agents ' , International Journal of Infectious Diseases , vol. 93 , pp. 268-276 . https://doi.org/10.1016/j.ijid.2020.02.018

Title: Discovery and development of safe-in-man broad-spectrum antiviral agents
Author: Andersen, Petter I.; Ianevski, Aleksandr; Lysvand, Hilde; Oksenych, Valentyn; Bjørås, Magnar; Telling, Kaidi; Lutsar, Irja; Dampis, Uga; Irie, Yasuhiko; Tenson, Tanel; Kantele, Anu; Kainov, Denis
Contributor: University of Helsinki, Norwegian University of Science & Technology (NTNU)
University of Helsinki, Department of Medicine
University of Helsinki, Institute for Molecular Medicine Finland
Date: 2020-04
Number of pages: 9
Belongs to series: International Journal of Infectious Diseases
ISSN: 1201-9712
URI: http://hdl.handle.net/10138/316038
Abstract: Viral diseases are one of the leading causes of morbidity and mortality in the world. Virus-specific vaccines and antiviral drugs are the most powerful tools to combat viral diseases. However, broad-spectrum antiviral agents (BSAAs, i.e. compounds targeting viruses belonging to two or more viral families) could provide additional protection of the general population from emerging and re-emerging viral diseases, reinforcing the arsenal of available antiviral options. Here, we review discovery and development of BSAAs and summarize the information on 120 safe-in-man agents in a freely accessible database (https://drugvirus.info/). Future and ongoing pre-clinical and clinical studies will increase the number of BSAAs, expand the spectrum of their indications, and identify drug combinations for treatment of emerging and re-emerging viral infections as well as co-infections. (C) 2020 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
Subject: 317 Pharmacy
Virus
Antiviral drug
Drug discovery and development
Broad-spectrum antiviral agents
BSAAs
ZIKA VIRUS-INFECTION
ANIMAL-MODELS
ROTAVIRUS INFECTION
SYSTEMATIC ANALYSIS
GLOBAL BURDEN
195 COUNTRIES
REPLICATION
INHIBITION
DISEASES
DRUGS
3121 Internal medicine
Rights:


Files in this item

Total number of downloads: Loading...

Files Size Format View
1_s2.0_S120197122030076X_main.pdf 5.877Mb PDF View/Open

This item appears in the following Collection(s)

Show full item record